Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Nutr Metab Cardiovasc Dis ; 23(9): 836-42, 2013 Sep.
Article in English | MEDLINE | ID: mdl-22902185

ABSTRACT

BACKGROUND & AIMS: Hyperhomocysteinaemia (HHCY), a common finding in patients with chronic kidney disease (CKD), has been shown to contribute to adverse cardiac remodelling and failure. We hypothesised that in human subjects with CKD, HHCY would be associated with myocardial dysfunction, and that homocysteine (HCY)-lowering therapy would improve myocardial remodelling and heart-failure (HF) outcomes. METHODS AND RESULTS: Post hoc analysis of the Homocysteinemia in Kidney and End Stage Renal Disease (HOST) trial (n=2056) was performed to determine if HCY-lowering therapy with high dose B vitamins affects HF outcomes in patients with CKD. In addition, effects on myocardial remodelling were assessed in a subgroup of 220 trial subjects who had transthoracic echocardiograms done before study randomisation and during the course of the study as part of their routine clinical care. HF outcomes were not significantly affected by treatment compared to the placebo. HCY levels were inversely correlated with diastolic function (R=-0.21; p=0.038). Vitamin therapy resulted in a significant increase in left atrial size (+0.15±0.8 cm vs. -0.13±0.07 cm; p=0.0095). No other echocardiographic parameters were significantly associated with baseline HCY levels or changes with vitamin therapy. CONCLUSION: HHCY is associated with diastolic dysfunction in patients with CKD. However, B-vitamin therapy did not improve HF outcomes despite lowering of plasma HCY levels, and was associated with an increase in left atrial size, which is a surrogate for worsening left ventricular diastolic dysfunction. These findings suggest that high-dose B vitamin therapy may be harmful in patients with CKD.


Subject(s)
Heart Failure/physiopathology , Hyperhomocysteinemia/drug therapy , Renal Insufficiency, Chronic/drug therapy , Vitamin B Complex/administration & dosage , Vitamin B Complex/adverse effects , Aged , Body Mass Index , Cohort Studies , Follow-Up Studies , Heart/drug effects , Heart/physiopathology , Heart Failure/etiology , Homocysteine/blood , Humans , Middle Aged , Prospective Studies , Regression Analysis , Serum Albumin/metabolism , Vitamins/administration & dosage , Vitamins/adverse effects
2.
FASEB J ; 22(11): 3888-95, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18711027

ABSTRACT

This pilot study examines noninvasive MR monitoring of tissue-engineered vascular grafts (TEVGs) in vivo using cells labeled with iron oxide nanoparticles. Human aortic smooth muscle cells (hASMCs) were labeled with ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles. The labeled hASMCs, along with human aortic endothelial cells, were incorporated into eight TEVGs and were then surgically implanted as aortic interposition grafts in a C.B-17 SCID/bg mouse host. USPIO-labeled hASMCs persisted in the grafts throughout a 3 wk observation period and allowed noninvasive MR imaging of the human TEVGs for real-time, serial monitoring of hASMC retention. This study demonstrates the feasibility of applying noninvasive imaging techniques for evaluation of in vivo TEVG performance.


Subject(s)
Aorta/cytology , Blood Vessel Prosthesis , Contrast Media/pharmacology , Iron/pharmacology , Magnetic Resonance Angiography/methods , Muscle, Smooth, Vascular/cytology , Myocytes, Smooth Muscle/cytology , Nanoparticles , Oxides/pharmacology , Tissue Engineering/methods , Animals , Dextrans , Ferrosoferric Oxide , Humans , Magnetite Nanoparticles , Mice , Mice, SCID
SELECTION OF CITATIONS
SEARCH DETAIL
...